SURVYR

ACAD

Acadia Pharmaceuticals Inc.
$20.17
+$0.43 (2.18%)Oct 27 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-20%-6%+7%+21%+35%Oct 2025Oct 2026Apr 202652w high $30.9652w low $18.39
ACADSPY
Wall St. Highest PT $37.00 (+83.4%) Wall St. Avg PT $30.53 (+51.3%)
$19$26$32$39$46POC $22Hi $37Avg $31
Underwater Drawdown %Max DD -39.1%Current -34.0%
0.0%-39.1%
Relative Strength vs SPY-25.8% vs SPYUnderperforming
+39%0%-39%
1W
−$0.27 (1.32%)
1M
−$0.51 (2.47%)
3M
−$5.84 (22.45%)
6M
−$2.50 (11.03%)
YTD
−$6.54 (24.49%)
1Y
−$2.82 (12.27%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
19 analysts · mean score 1.90
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$20.17
Average target$30.53
+$10.36 (+51.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$16.00
Median$30.53
High$37.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-19 · Needham reiterated Buy on ACAD
Downgrade
2026-10-13 · UBS downgraded ACAD from Buy to Neutral
Reiterated
2026-10-08 · RBC Capital reiterated Outperform on ACAD
Reiterated
2026-09-25 · Deutsche Bank reiterated Buy on ACAD
Reiterated
2026-09-25 · HC Wainwright & Co. reiterated Buy on ACAD
Reiterated
2026-09-25 · Citizens reiterated Market Outperform on ACAD
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$3.5B
P/E (last 12 months)9.1
P/E (next 12 months, estimated)21.9
52-week range$18.39 – $30.96
Revenue growth (latest quarter vs a year ago)+16.4%
Dividend yieldNo dividend
Analyst consensusBuy (19)
Average analyst price target$30.53 (+51%)

What they do

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
20th percentile in sector
D
12-1 return: -11.2%
Percentile within its GICS sector across the S&P 1500.
Growth
74th percentile in sector
B+
Revenue growth (YoY): +16.4%
Percentile within its GICS sector across the S&P 1500.
Value
29th percentile in sector
D+
Forward E/P: 4.8% · EBITDA/EV: 4.1%
Percentile within its GICS sector across the S&P 1500.
Profitability
91st percentile in sector
A
Profit margin: +33.4% · Return on equity: +35.7%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ACAD earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus$0.18 range $0.11–$0.29
Revenue consensus$332.6M 18 analysts
Last 4 quarters · EPS vs estimate
Aug 4, 2026$0.18est $0.04+317.2%Above estimates
May 6, 2026$0.02est $0.08−75.2%Below estimates
Feb 25, 2026$0.14est $0.14−4.2%In line with estimates
Nov 5, 2025$0.42est $0.15+189.0%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 18:22:37 ET
24-1125-0225-0525-0825-1126-0226-0526-080.000.86
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$308.0M+16.4%
2026-03-31$268.1M–
2025-12-31$284.0M–
2025-09-30$278.6M–
2025-06-30$264.6M–

News & catalysts

More news
Acadia Pharmaceuticals (ACAD) files 8-K: executive or board change
SEC 8-K · Oct 23
Rating changes
Reiterated
2026-10-19 · Needham reiterated Buy on ACAD
Downgrade
2026-10-13 · UBS downgraded ACAD from Buy to Neutral
Reiterated
2026-10-08 · RBC Capital reiterated Outperform on ACAD
Reiterated
2026-09-25 · Deutsche Bank reiterated Buy on ACAD
Reiterated
2026-09-25 · HC Wainwright & Co. reiterated Buy on ACAD
Reiterated
2026-09-25 · Citizens reiterated Market Outperform on ACAD

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER · 2026-08-06
Sell
$272.6K
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER · 2026-08-06
Sell
$145.0K
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER · 2026-08-05
Sell
$169.6K
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev · 2026-07-30
Sell
$1.3K
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev · 2026-07-30
Sell
$431.4K

Stats refreshed 2026-10-21 18:22:37 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026